Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 17/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621814 | 0.91 | HCRTR1 (0.83) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3622240 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3621999 | 0.86 | HCRTR1 (0.75) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3624251 | 0.86 | HCRTR1 (0.77) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3615560 | 0.84 | HCRTR2 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3622216 | 0.84 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3621447 | 0.84 | HCRTR1 (1.00) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3624546 | 0.84 | HCRTR1 (0.77) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3622189 | 0.84 | HCRTR1 (0.75) | HCRTR1HCRTR2HTR1AOPRM1DRD3 | |
| SCHEMBL3612984 | 0.83 | HCRTR1 (0.90) | HCRTR1HCRTR2HTR1AOPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | claimed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | claimed |
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410142-B2 | Bipyridine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-03-11 | — | — | US | disclosed |
| WO-2008108991-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063056-A1 | BIPYRIDINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR1 | HCRTR1 2/4885HCRTR2 1/4885HTR1A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.